HIV-1 receptors and cell tropism

British Medical Bulletin

Volumn 58, Issue , 2001, Pages 43-59

  Clapham, Paul R ^a   McKnight, Áine ^b  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CELL SURFACE RECEPTOR; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; MANNOSE BINDING PROTEIN; VIRUS RECEPTOR;

BINDING SITE; CELL COMPARTMENTALIZATION; CELL GROWTH; DENDRITIC CELL; DRUG RECEPTOR BINDING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REVIEW; TARGET CELL; VIRUS PARTICLE; VIRUS REPLICATION; VIRUS TRANSMISSION;

ANTIGENS, CD4; DENDRITIC CELLS; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; MACROPHAGES; RECEPTORS, CCR5; RECEPTORS, HIV; T-LYMPHOCYTES; TROPISM; VIRUS REPLICATION;

EID: 0035173908     PISSN: 00071420     EISSN: None     Source Type: Journal    
DOI: 10.1093/bmb/58.1.43     Document Type: Review

References (89)

1. Host genetic influences on HIV-1 pathogenesis
2. Mechanism of transdominant inhibition of CCR5-mediated HIV-1 infection by CCR5 delta32
3. A 32-bp deletion within the CCR5 locus protects against transmission of parenterally acquired human immunodeficiency virus but does not affect progression to AIDS-defining illness
4. CCR5 genotype and resistance to vertical transmission of HIV-1
5. Exclusive and persistent use of the entry coreceptor CXCR4 by human immunodeficiency virus type 1 from a subject homozygous for CCR5 delta32
6. In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression
7. Expression and coreceptor activity of STRL33/BONZO on primary peripheral blood lymphocytes
8. CCR8 on human thymocytes functions as a human immunodeficiency virus type 1 coreceptor
9. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody
10. Stable exposure of the coreceptor-binding site in a CD4-independent HIV-1 envelope protein
11. The CD4 independent tropism of HIV-2 involves several regions of the envelope protein and correlates with a reduced activation threshold for envelope mediated fusion
12. Replication and neutralization of human immunodeficiency virus type 1 lacking the V1 and V2 variable loops of the gp120 envelope glycoprotein
13. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5
14. Identification of determinants on a dual tropic human immunodeficiency virus type 1 envelope glycoprotein that confer usage of CXCR4
15. Epitope mapping of CCR5 reveals multiple conformational states and distinct but overlapping structures involved in chemokine and coreceptor function
16. Fusion of monocytes and macrophages with HIV-1 correlates with biochemical properties of CXCR4 and CCR5
17. Constitutive cell surface association between CD4 and CCR5
18. Regions in beta-chemokine receptors CCR5 and CCR2b that determine HIV-1 cofactor specificity
19. Multiple extracellular domains of CCR-5 contribute to human immunodeficiency virus type 1 entry and fusion
20. Differential utilization of CCR5 by macrophage and T cell tropic simian immunodeficiency virus strains
21. Role of the amino-terminal extracellular domain of CXCR-4 in human immunodeficiency virus type 1 entry
22. Role of the first and third extracellular domains of CXCR-4 in human immunodeficiency virus coreceptor activity
23. Effect of mutations in the second extracellular loop of CXCR4 on its utilization by human and feline immunodeficiency viruses
24. A tyrosine-rich region in the N terminus of CCR5 is important for human immunodeficiency virus type 1 entry and mediates an association between gp120 and CCR5
25. CXCR4 sequences involved in coreceptor determination of human immunodeficiency virus type-1 tropism. Unmasking of activity with M-tropic Env glycoproteins
26. Macrophage tropism: Fact or fiction?
27. Primary, syncytium-inducing human immunodeficiency virus type 1 isolates are dual-tropic and most can use either Lestr or CCR5 as coreceptors for virus entry
28. The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes
29. +) T cells are infected in human immunodeficiency virus type 1-infected individuals
30. The reservoir for HIV-1 in human peripheral blood is a T cell that maintains expression of CD4
31. Detection of infectious HIV in circulating monocytes from patients on prolonged highly active antiretroviral therapy
32. Monocytes harbour replication-competent, non-latent HIV-1 in patients on highly active antiretroviral therapy
33. HIV: The deadly passenger in dendritic cells
34. HIV-1 Langerhans' cell tropism associated with heterosexual transmission of HIV
35. Different subtypes of HIV-1 and cutaneous dendritic cells
36. Subpopulations of peripheral blood dendritic cells show differential susceptibility to infection with a lymphotropic strain of HIV-1
37. Immature dendritic cells selectively replicate macrophage tropic (M-tropic) human immunodeficiency virus type 1, while mature cells efficiently transmit both M- and T-tropic virus to T cells
38. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells
39. +, T-cell clones correlates with the clinical state of human immunodeficiency virus type 1 (HIV-1)-infected individuals and may be responsible for blocking infection with non-syncytium-inducing HIV-1 in vitro
40. Constitutive expression of stromal derived factor-1 by mucosal epithelia and its role in HIV transmission and propagation
41. Unraveling the neuroimmune mechanisms for the HIV-1-associated cognitive/motor complex
42. Overexpression of nef as a marker for restricted HIV-1 infection of astrocytes in postmortem pediatric central nervous tissues
43. HIV infection of human brain capillary endothelial cells - Implications for AIDS dementia
44. HIV-1 entry inhibitors: Evading the issue
45. A broad-spectrum chemokine antagonist encoded by Kaposi's sarcoma-associated herpes virus
46. Natural infection of a homozygous delta24 CCR5 red-capped mangabey with an R2b-tropic simian immunodeficiency virus
47. Co-receptor use by HIV and inhibition of HIV infection by chemokine receptor ligands
48. Complex determinants of macrophage tropism in env of simian immunodeficiency virus
49. Derivation of neurotropic simian immunodeficiency virus from exclusively lymphocytotropic parental virus: Pathogenesis of infection in macaques
50. Analysis of envelope changes acquired by SIVmac239 during neuroadaption in rhesus macaques
51. Genetic differences between blood- and brain-derived viral sequences from human immunodeficiency virus type 1-infected patients: Evidence of conserved elements in the V3 region of the envelope protein of brain-derived sequences
52. Demented and non-demented patients with AIDS differ in brain-derived human immunodeficiency virus type 1 envelope sequences
53. Chemokine receptors and mechanisms of cell death in HIV neuropathogenesis
54. Genomic variation of human immunodeficiency virus type 1 (HIV-1): Molecular analyses of HIV-1 in sequential blood samples and various organs obtained at autopsy
55. Human immunodeficiency virus type 1 populations in blood and semen
56. Human immunodeficiency virus in semen arises from a genetically distinct virus reservoir
57. Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120
58. Biological characterization of human immunodeficiency virus type 1 clones derived from different organs of an AIDS patient by long-range PCR
59. Human immunodeficiency virus type 1 coreceptors participate in post entry stages in the virus replication cycle and function in simian immunodeficiency virus infection
60. Restricted replication of simian immunodeficiency virus strain 239 in macrophages is determined by env but is not due to restricted entry
61. Macrophage-tropic HIV and SIV envelope proteins induce a signal through the CCR5 chemokine receptor
62. The level of CD4 expression limits infection of primary rhesus monkey macrophages by a T-tropic simian immunodeficiency virus and macrophagotropic human immunodeficiency viruses
63. Oligosaccharide-mediated interactions of the envelope glycoprotein gp120 of HIV-1 that are independent of CD4 recognition
64. Inhibition of entry of HIV-1 in neural cell lines by antibodies against galactosyl ceramide
65. Infection of colonic epithelial cell lines by type 1 human immunodeficiency virus is associated with cell surface expression of galactosylceramide, a potential alternative gp120 receptor
66. A monoclonal antibody directed to sulfatide inhibits the binding of human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein to macrophages but not their infection by the virus
67. Co-expression of CXCR4/fusin and galactosylceramide in the human intestinal epithelial cell line HT-29
68. Human immunodeficiency virus type 1 attachment to HeLa CD4 cells is CD4 independent and gp120 dependent and requires cell surface heparans
69. Selective interactions of polyanions with basic surfaces on human immunodeficiency virus type 1 gp120
70. Soluble CD4 blocks the infectivity of diverse strains of HIV and SIV for T cells and monocytes but not for brain and muscle cells
71. Dissociation of gp120 from HIV-1 virions induced by soluble CD4
72. High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates
73. Virions of primary human immunodeficiency virus type 1 isolates resistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and glycoprotein gp120 retention from sCD4-sensitive isolates
74. Phase I study of continuous-infusion soluble CD4 as a single agent and in combination with oral dideoxyinosine therapy in children with symptomatic human immunodeficiency virus infection
75. The safety and pharmacokinetics of recombinant soluble CD4 (rCD4) in subjects with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase 1 study
76. Recombinant soluble CD4 therapy in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase I-II escalating dosage trial
77. Prevention of HIV-1 IIIB infection in chimpanzees by CD4 immunoadhesin
78. Phase 1 study of recombinant human CD4-immunoglobulin G therapy of patients with AIDS and AIDS-related complex
79. Primary HIV-1 isolates refractory to neutralization by soluble CD4 are potently inhibited by CD4-Pseudomonas exotoxin
80. Failure of short-term CD4-PE40 infusions to reduce virus load in human immunodeficiency virus-infected persons
81. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG
82. Effective ex vivo neutralization of human immunodeficiency virus type 1 in plasma by recombinant immunoglobulin molecules
83. CCR5/delta (ccr5) heterozygosity: A selective pressure for the syncytium-inducing human immunodeficiency virus type 1 phenotype
84. Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist
85. Aminooxypentane-RANTES induces CCR5 internalization but inhibits recycling: A novel inhibitory mechanism of HIV infectivity
86. A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor
87. A small molecule CXCR4 inhibitor that blocks T cell line-tropic HIV-1 infection
88. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity
89. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor